The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here:

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Carina Törn


Default user image.

Combinations of beta cell specific autoantibodies at diagnosis of diabetes in young adults reflects different courses of beta cell damage


  • Carina Törn
  • Mona Landin-Olsson
  • Åke Lernmark
  • Bengt Scherstén
  • J. Ostman
  • H.J. Arnqvist
  • E. Bjork
  • G. Blohme
  • J. Bolinder
  • J. Eriksson
  • Bengt Littorin
  • L. Nyström
  • Göran Sundkvist

Summary, in English

To explore the natural course of beta cell function in recent onset diabetes, a subgroup (n = 157) of all incident cases (n = 879) 15-34 years old. 1992-1993 in Sweden. and with positivity for at least one autoantibody of islet cell antibodies (ICA), glutamic acid decarboxylase antibodies (GADA) or tyrosine phosphatase antibodies (1A-2A) were followed prospectively thr the first four years with annual analysis of C-peptide. The aim was to relate the course of beta cell function, measured as C-peptide, in early diabetes with the presence of different islet autoantibodies at diagnosis. We found that patients positive for ICA alone (n = 11 ) had significantly higher C-peptide levels both at diagnosis and during the first three years compared with the other patients (n = 146; p = 0.022, p < 0.001, p = 0.004 and p = 0.0022). Patients positive for GADA alone or in combination with other antibodies (n = 125) had significantly lower C-peptide during the first three years after diagnosis compared with the other patients (n = 32. p < 0.001, p = 0.0011 and p = 0.0136). Patients with two or three autoantibodies had C-peptide levels similar to levels found in patients positive only for GADA. However. after four years, there were no significant differences between any of the groups of different autoantibody combinations. At diagnosis. 55% (86/157) of the patients had C-peptide: levels above the lower normal range of 0.25 nmol/l, but the frequency of patients with beta cell Function above this level decreased after two years to 41% (65/157; p = 0.035) and after four years to 22% (35/157; p = 0.0041).


  • Celiac Disease and Diabetes Unit
  • Medicine, Lund
  • Family Medicine and Community Medicine
  • Department of Clinical Sciences, Malmö

Publishing year












Document type

Journal article


Taylor & Francis


  • Rheumatology and Autoimmunity



Research group

  • Diabetes and Celiac Unit
  • Family Medicine and Community Medicine


  • ISSN: 0891-6934